Kornimate/medical-research-clean huggingface dataset:
comparison of the effects of trigger point ischemic compression massage and focused extracorporeal shoch wave therapy of the patients with lateral epicondylitis: a randomized controlled trial

Conditions: Lateral Epicondylitis

Summary: to compare the effects of trigger point ischaemic compression massage (tpicm) and focused extracarporeal shock wave therapy (focused eswt) on pain level, muscle strength, joint range of motion, functionality and quality of life in patients with lateral epicondylitis (le) in a randomised controlled trial.

the study was planned to include at least 66 patients who presented to the sports medicine clinic of gülhane training and research hospital with lateral epicondyle pain for at least 2 months, were diagnosed with lateral epicondylitis and verbally and in writing declared that they were willing to participate in the study. patients participating in the study; 1. assessment of pain intensity with visual analog scale (vas) 2. evaluation of hand grip strength with jamar hand dynamometer 3. isokinetic muscle strength assessment of wrist muscles with biodex isokinetic system 3 4. assessment of wrist range of motion with a manual goniometer 5. function assessment with prtee-t 6. dash questionnaire 7. sf-36 quality of life assessment will be performed before and after treatment. inclusion criteria 1. male and female individuals aged 18-60 years 2. being diagnosed with lateral epicondilitis 3. volunteering to participate in the study exclusion criteria from eswt treatment 1. non-cooperation 2. presence of systemic and metabolic diseases 3. malignancy, osteoporosis, fracture, blood clotting disorder, pacemaker, infection 4. pregnancy 5. utilization of another treatment for lateral epicondylitis during the study period 6. previous invasive treatment with steroids for lateral epicondylitis 7. any treatment for lateral epicondylitis in the last 6 months

Eligibility criteria:
inclusion criteria: 1. male and female individuals between the ages of 18-60 2. being diagnosed with lateral epicondylitis 3. volunteering to participate in the study exclusion criteria: 1. non-cooperation 2. presence of systemic and metabolic diseases 3. malignancy, osteoporosis, fracture, blood clotting disorder, pacemaker, infection 4. pregnancy 5. utilization of another treatment for lateral epicondylitis during the study period 6. previous invasive treatment with steroids for lateral epicondylitis 7. any treatment for lateral epicondylitis in the last 6 months

Keywords: lateral epicondylitis trigger points ıschemıc compressıon massage focus eswt
evaluate the intestinal microbiome in patients with erosive gastroesophageal reflux disease and in asymptomatic healthy controls

Conditions: Gastroesophageal Reflux Disease With Esophagitis

Summary: . in this study, we investigated intestinal microbiomes, in individuals with gastroesophageal reflux disease and healthy individuals, using metagenomic techniques.

background: the pathophysiology of gastroesophageal reflux disease (gerd) involves several mechanisms. intestinal dysbiosis may influence factors involved in the pathophysiology of gastroesophageal reflux disease, such as changes in gastrointestinal motor patterns and increased intraabdominal pressure due to increased fermentation of non-digestible carbohydrates. however, few studies have focused on assessment of gut microbiome in the gerd. in this study, we investigated intestinal microbiomes, in individuals with gastroesophageal reflux disease and healthy individuals, using metagenomic techniques. methods: we performed a study comprising fecal samples of 22 adults, aged 18-60 years: 11 with erosive esophagitis (eight male and three female) and 11 healthy controls (ten male and one female). microbiome dna was extracted from stool samples, and polymerase chain reaction amplification was performed using primers for the v4 region of the 16s rrna gene (16s ribosomal ribonucleic acid). the amplicons were sequenced using the ion torrent™ personal genome machine™ platform, and data were analyzed using qiime™ software version 1.8 (quantitative insights into microbial ecology).

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of erosive gerd through clinical and endoscopic criteria * who have not taken omeprazole or any other drug that changes gastric ph in the thirty days prior to the completion of diagnostic tests for gerd and other tests included in the protocol. exclusion criteria: * use of antimicrobials or probiotics in the last three months * presence of severe and/or extensive atrophic gastritis confirmed histologically * comorbidities that could interfere with motility of the gastrointestinal tract (diabetes mellitus, previous stroke, neurological diseases) * use of drugs that could interfere with motility of the gastrointestinal tract or salivation (calcium channel blockers, nitrates, anticholinergics, estrogens) * bulky hiatal hernia (greater than or equal to 5 cm) * los angeles grade c or d erosive esophagitis * long-distance travel in the last 3 months (outside the southeastern region of the country) * pregnant or breastfeeding patients * previous history of upper digestive tract surgery * obesity (body mass index equal to or greater than 30 kg / m2) * patient with a consumptive syndrome or malnutrition * tobacco use in the last 30 days / alcohol use (more than 20 g per day, in the last 30 days)

Keywords: gastroesophageal reflux intestinal microbiome
risk-based therapy for sickle cell anemia: a feasibility study

Conditions: Sickle Cell Anemia

Summary: sickle cell anemia (sca) patients experience organ damage that begins at an early age and results in significant morbidity and early mortality. although all sca patients share the same genetic mutation, the clinical complications are highly variable with some patients experiencing frequent and severe complications, while others have few serious complications. if sca severity could be predicted early in life, those patients at greatest risk for complications could receive treatment prior to the onset of organ damage. no general sca severity predictor or one that can be informative early in life exists. the investigators preliminary research has identified the absolute reticulocyte count (arc) as a potential early predictive risk marker for sca complications in pediatric patients. a higher arc between ages 2 and 6 months of age is associated with an increased risk of hospitalization in the first 3 years of life; the mean arc for the 36 patients who were hospitalized for sca complications was significantly higher than that of the remaining 23 in those who were not hospitalized. moreover, total hospitalizations were nearly three times higher by age 2 years in those infants who had an arc of \> 200 than for those infants whose arc was \<200. the proposed study will determine if arc can be used as a risk-stratifier in asymptomatic infants with sca and ascertain its value in targeting hydroxyurea therapy to those infants at highest risk of sca sequelae.


Eligibility criteria:
inclusion criteria: * ages 6-12 months * sickle cell anemia (hbss) * steady state absolute reticulocyte count between 2-6 months is available in the medical record exclusion criteria: * receiving hydroxyurea or chronic monthly blood transfusions * patient enrolled in preliminary study
comparison of superior hypogastric plexus block and peritoneal bupivacaine in pain management

Conditions: Superior Hypogastric Plexus Block; Intraperitoneal Bupivacaine

Summary: background: laparoscopic hysterectomy is one of the most frequently performed major surgeries in nonmalignant gynecological diseases. effective postoperative analgesia is associated with short hospital stays, early mobilization, reduced costs, and patient satisfaction. intravenous administration of nonsteroidal anti-inflammatory drugs, paracetamol or opioids; epidural catheter placement; peritoneal local anaesthetic administration; and superior hypogastric plexus block (shpb) are routinely employed methods for postoperative pain management following laparoscopic hysterectomy. methods: the study population comprised patients who underwent laparoscopic hysterectomy with or without oophorectomy for benign indications. a total of 94 patients were included in the study. thirty patients received a superior hypogastric plexus block, thirty received intraperitoneal local anaesthetic spray, and thirty-four received intravenous analgesics. conclusion: in the present study, a comparison of postoperative pain management in patients who underwent laparoscopic hysterectomy was conducted.

in the present study, a comparison of postoperative pain management in patients who underwent laparoscopic hysterectomy was conducted. the findings indicated that the initial postoperative administration of analgesics occurred later in patients who received peritoneal local anesthetics and shpb compared to the control group. in addition, vas values at the first and third hours were found to be lower in the peritoneal local anesthetic and shpb groups than in the control group. postoperative pain experienced by patients following gynecologic surgery. it has been reported that approximately 75% of patients experience severe pain. excessive opioid use in postoperative pain management and the potential for additional complications are also possible. one of the alternative methods to reduce postoperative opioid use is intraperitoneal bupivacaine administration.

Eligibility criteria:
inclusion criteria: * patients who underwent laparoscopic hysterectomy-with or without oophorectomy- * asa physical status i-ii patients exclusion criteria: * women with known bupivacaine allergy, anxiety-depressive disorders, fibromyalgia, coagulopathy, eclampsia/preeclampsia, or those who were pregnant were also excluded. * if they were younger than 18 or older than 65 * underwent epidural catheterisation and/or received additional pain management modalities * prescribed preoperative antidepressants or gabapentinoids

Keywords: hypogastric plexus hysterectomy intraperitoneal injections
use bronchoscopy to predict post-extubation stridor in critical ill patients

Conditions: Post-Extubation Stridor

Summary: our study aims at the accuracy of bronchoscopy to predict pes. evidence base medicine guidelines for extubation may be obtained through this study.


Eligibility criteria:
inclusion criteria: * age equal or greater than 18 years old * intubation over 24 hrs * match weaning profile * cuff leak volume less than 24% * vs and subject/family agree exclusion criteria: * re-intubation * history of upper air way obstruction * severe cv disease (ex. ami) * active ugi bleeding * blood sugar persistent more than 250 mg/dl under medication control * risk of iicp * open t.b. * bleeding tendency/ platelet less than 40 thousands * subject or family refuse

Keywords: endotracheal intubation cuff-leak test post-extubation stridor bronchoscopy corticosteroids cuff-leak volume less than 24%
efficacy of fixed combination therapy of vildagliptin and metformin compared to the individual monotherapy components in drug naive patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes


Eligibility criteria:
inclusion criteria: * male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes * diagnosis of t2dm for at least 4 weeks prior to study entry * age 18 - 78 years inclusive * body mass index (bmi) of 22 - 40 kg/m2 * hba1c: 7.5 - 11% inclusive * fpg \<270 mg/dl (15 mmol/l) exclusion criteria * pregnant or lactating female * a history of type 1 diabetes * evidence of significant diabetic complications * other protocol-defined inclusion/exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin metformin hemoglobin a1c
clinical study of et019002-t cell therapy for refractory/relapsed b-cell malignancies

Conditions: B-Cell Malignancies

Summary: this study is to determine the safety, including potential dose limiting toxicities, and efficiency of et019002-t cells and the duration of in vivo survival of et019002-t cells in patients with relapsed/refractory b-cell malignancies.

et019002-t cell therapy is a novel chimeric t-cell therapy platform that in preclinical studies, functionally matches the efficacy of car-t cells, but dramatically reduces the release of cytokines upon killing of target-positive tumors.the arm of the study is experimental i.v. arm:et019002-t cells administered by intravenous (iv) infusion.the intervention is et019002-t cells(autologous t cells transduced with lentivirus encoding an anti-cd19 (et019002)-expression construct).

Eligibility criteria:
inclusion criteria: * diagnosed b cell malignancies including: b-cell acute lymphoblastic leukemia (b-all) and b cell lymphomas (dlbcl、fl、mzl、lpl、hcl、cll、bl、mcl) * refractory/relapsed b cell malignancies: * age 6-80 years, male or female * nidus could be evaluated: minimum diameter of single nidus ≥10mm, and/or tumor cells in bone marrow ≥ 5% * ecog≤2 points * function of main organs or tissues were functional: liver - alt/ast≤3 normal upper limit, serum total bilirubin (tbil) ≤2 normal upper limit; kidney - glomerular filtration rate (gfr) \> 60 ml/min/1.73 m2 or serum creatinine in normal range; lunge - carbon monoxide diffusion capacity (dlco) or forced expiratory volume in 1s (fev) \>45% estimate; heart - left ventricular ejection fraction (lvef) ≥50% * expecting life span ≥3 months * no chemotherapy, radiation therapy or immunotherapy in 2 weeks before enrollment * fertile females/males consented to use contraceptives during participation of the trial * patient or his/her custodia could understand and is willing to sign the written consent exclusion criteria: * pregnancy or lactation * couldn't use contraceptives during participation of the trial * couldn't collect enough monocyte * active and/or severe infection * hiv infection, active hepatitis b or hepatitis c infection * had active autoimmune disease * had non-melanoma skin carcinoma (nmsc) or carcinoma in situ (e.g. cervix, bladder, galactophore) * obvious clinical encephalopathy or novel neuron function damage * organ failure: heart - upper than nyha level iii or had uncontrolled malignant arrhythmia; liver - upper than level iii of wuhan conference classification; kidney - kidney failure stage3 or worse * using immunosuppressive drugs or adreno-cortical hormone (ach) within two weeks of enrollment * insufficient t cell number or t cell transfection rate * needed urgent disease controlling due to tumor load * patients had biological treatment, immunotherapy or radiation therapy within 6 weeks prior to enrollment or are currently under these treatment * substance abuse or drug addiction * lack of compliance, communication deficit or other unaccommodated situations
an expanded access protocol for subjects who have completed clinical studies involving maraviroc

Conditions: Infection, Human Immunodeficiency Virus

Summary: this is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.


Eligibility criteria:
inclusion criteria: * evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * subject has participated in a clinical trial that evaluated maraviroc and is continuing to derive clinical benefit from maraviroc treatment. * subject must agree to use an acceptable method of contraception for the duration of the study as outlined at the end of the inclusion criteria. * subject agrees to the specified study procedures. exclusion criteria: * subject who is an investigational site staff member or an employee of the sponsor that is directly involved in the conduct of the trial. * other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. * contra-indications to use of maraviroc as described in the investigator brochure. * past documented dual/mixed or c-x-c chemokine receptor type 4 hiv tropism.

Keywords: expanded access, hiv, maraviroc
saline at different temperatures after 3rd molar surgery

Conditions: Post Operative Pain, Acute

Summary: this double-blind, single-center, split-mouth, randomized prospective clinical trial was conducted among 48 systemically and periodontally healthy patients who had bilaterally asymptomatic mandibular third molars.

patients were randomly allocated into 2 groups (n = 24) according to the temperature of the saline used. in each patient, one impacted third molar was determined as the test group trismus and swelling were evaluated on the 1st, 3rd, and 7th days postoperatively. pain perception by visual analog scale (vas) and the total number of analgesics taken during the 7 postoperative days were recorded. data were analyzed using the shapiro-wilk test, the chi-square test, one-way analysis of variance, duncan test, the kruskal-wallis test, the dunn test, and the friedman test (p \< .05).

Eligibility criteria:
inclusion criteria:1. patients who met the requirements of the study, such as attending follow-up sessions and signing the informed consent. 2. patients with bilateral mandibular asymptomatic vertical third molar teeth with impaction of class i, level c.22 3. patients who did not have any significant medical diseases or drug use, were not pregnant, had no allergy, and did not smoke. - exclusion criteria: 1 patients with complicating systemic disease ( american society of anesthesiologists : 3- 6). 2. patients who have second molars with severe periodontal defect or deep periodontal pocket (probing depth \>4 mm). 3. patients with poor oral hygiene. 4. patients with a history of using analgesics 12 hours ago or antibiotics 1 month before. 5. the presence of cysts or tumors around the impacted third molar. -

Keywords: 3rd molar surgery, saline irrigation at different temperatures
study on antigen-presenting function of gamma delta t cells in sepsis and its molecular mechanisms

Conditions: Sepsis; Antigen-presenting Function; γδ T Cells

Summary: study on antigen-presenting function of gamma delta t cells in sepsis and its molecular mechanisms

the latest definition of sepsis highlights the role of dysregulated host response to infection in organ dysfunction aggravation. maintenance of immune homeostasis of septic patients through immunotherapy is the key breakthrough to improve success rate. antigen-presenting cell (apc) is the bridge that connects the innate and adaptive immunity. decrease of count and function of apc has been shown to be associated with worsened clinical outcomes in patients with sepsis. gamma-delta t cells (γδ t cells) are the newly identified population of t lymphocytes. recent studies have found that γδ t cells possess unique and powerful antigen-presenting function, making them the hot topic in infection and cancer research. based on the results, the investigator plan to evaluate the antigen-presenting function changes of γδ t cells in septic status by analyzing the antigen-presenting related molecules on γδ t cells, antigen protein uptake ability, and their function on the proliferation and activation of cd8+ t lymphocytes. furthermore, the investigator will explore the mechanism and signal pathways for the apc function changes of γδ t cells. findings from this research could help explain the mechanism of sepsis induced immune dysfunction, enrich our understanding of the important role of γδ t cells, and build a good foundation for immunotherapy in sepsis.

Eligibility criteria:
inclusion criteria: 1. ≥18 year old; 2. a known or suspected infection based on clinical data at the time of admission and sepsis-induced dysfunction of at least one organ. exclusion criteria: 1. autoimmune disease, 2. history of transplantation, 3. acute tuberculosis, 4. chronic hepatitis b or c infection, 5. hiv infection, 6. active malignancy, and 7. long-term use of cortical steroids.
homemade fenestrated physician-modified stent-grafts for arch aortic degenerative aneurysm

Conditions: Aortic Arch Aneurysm

Summary: the aim was to evaluate early and medium-term outcomes of single and double fenestrated physician-modified endovascular grafts (pmegs) for endovascular aortic arch degenerative aneursym repair. the evolution of stent-graft technology recently has meant the development of custom-made branched stent-grafts to achieve total endovascular aortic arch repair for high-risks patients. the disadvantages of custom-made include manufacture and deliver times for urgent cases and the associated high costs. unfortunately there is also a high rate of embolization associated with this approach probably related to the complexity of deploying a multi-branched unibody stent-graft. a further alternative is physician modified endografts (pmegs) for zone 0 tevar involving the deployment of a conventional stent-graft device ex-vivo, fashioning of customized fenestrations (for supra aortic trunk) and re-constrainment into the delivery system. the authors have previously shown the feasability in vitro and they have reported their experience for arch aortic lesion. the aim of this study is to evaluate the outcomes for aortic arch degenerative aneursym repair which is the most risky procedure


Eligibility criteria:
inclusion criteria: - patients operated on in our department between 2000 and january 2020 for a thoracic endoprosthesis exclusion criteria: - patient who reject the study protocol

Keywords: proximal descending aorta aneurism proximal and distal neck (length >20mm et diameter >20mm and <40mm thoracic endovascular aortic repair intra-abdominal septic complications
pulmonary diffusing capacity during acute exercise in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the combined measurement of the pulmonary diffusing capacity to carbon monoxide (co) and nitric oxide (no) (dlco/no) during exercise may be a useful physiological measure of alveolar-capillary reserve in patients with chronic obstructive pulmonary disease (copd). the present study investigated the test-retest reliability of dlco/no-based metrics.

the combined measurement of the pulmonary diffusing capacity to carbon monoxide (co) and nitric oxide (no) (dlco/no) has recently been standardised and validated for clinical use. it is thus ideal for assessing acute changes in pulmonary diffusing capacity and its components during various physiological manoeuvres. these changes are thought to involve acute changes in pulmonary perfusion and are notably relevant for patients with chronic obstructive pulmonary disease (copd), in which they may be related to exertional dyspnoea. the aim of the present study is to investigate the effects of acute exercise on pulmonary diffusing capacity, and to determine the day-to-day repeatability of such assessments.

Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease (gold ii + iii) exclusion criteria: * known heart disease * pregnancy * disease within two weeks prior to inclusion

Keywords: pulmonary diffusing capacity reliability test-retest